Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (481-490 of 713) with videos related to

Pageof 72
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
International Journal of Molecular Sciences|September 22, 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid LeukemiaMaliha Khan, Jorge Cortes, Tapan Kadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patientsApostolia-Maria Tsimberidou, Hagop M Kantarjian, Sijin Wen, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.
Nefrologia|November 27, 2022
Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategyCamilo Montero, Nancy Yomayusa, Rodolfo Torres, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Pageof 72

Showing results (481-490 of 713) with videos related to

Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
International Journal of Molecular Sciences|September 22, 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid LeukemiaMaliha Khan, Jorge Cortes, Tapan Kadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patientsApostolia-Maria Tsimberidou, Hagop M Kantarjian, Sijin Wen, et al.
Leukemia & Lymphoma|March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.
Nefrologia|November 27, 2022
Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategyCamilo Montero, Nancy Yomayusa, Rodolfo Torres, et al.
Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.
Blood|April 20, 2004
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantationMarcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Pageof 72